| |
|
Form Serial No: |
DA20170623000318 |
| 1.
Name of listed corporation: |
WuXi Biologics (Cayman) Inc. |
| 2.
Stock code: |
02269 |
| 3.
Class of shares: |
Ordinary Shares |
| 4.
Number of issued shares in class: |
1,163,065,057 |
| 5.
Name of director (English) as printed on HKID/Passport: |
| (Surname) |
Li |
| (Other names) |
Ge |
|
|
|
| 8.
Name of director (Chinese): |
李革 |
| 9.
Chinese Character Code: |
|
| 12.
Date of relevant event: |
19/06/2017
(dd/mm/yyyy)
|
| 13.
Date when director became aware of the relevant event/ interest in the shares (if later): |
|
| |
| 14.
Details of relevant event: |
|
|
Relevant event code describing circumstances
|
Code describing capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price per share
|
Average price per share
|
Average consideration per share
|
Consideration code
|
| Long position |
126 |
205 |
205 |
28,947,000 |
HKD |
|
|
|
|
| |
|
| 15.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long Position | 913,991,668 | 80.59 |
|
| |
| 16.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long Position | 913,991,668 | 78.58 |
|
| |
| 17.
Capacity in which interests disclosed in Box 16 are held (required for Initial Notification only): |
| Code describing capacity | Number of shares |
| 205 | |
| 211 | |
|
| |
| 18.
Further information in respect of derivative interests in listed corporation: |
| Code describing derivatives |
Exercise period |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Price for grant | Exercise price | Price on assignment | |
| Nil | | | | | | | |
|
| |
| 19.
Further information in relation to interests of children under 18 and/or spouse: |
| Name of child/spouse | Number of shares |
| Nil | |
|
| |
| 20.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling shareholder | % control | Direct interest | Number of shares |
| WuXi Biologics Holdings Limited | Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands | Ge Li | 56.82 | Y | |
| G&C VII Limited | PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands | New WuXi ESOP L.P. | 100.00 | Y | |
| New WuXi ESOP L.P. | PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands | G&C Limited | 100.00 | N | |
| G&C Limited | PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands | Ge Li | 100.00 | N | |
|
| |
| 21.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| Nil | | |
|
| |
| 22.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| Nil | | | |
|
| |
| 23.
Further information from a party to an agreement under Section 317: |
| Names of other parties | Address | Number of shares |
| Zhaohui Zhang | Addresses of individuals are not displayed. | 1,778,544 |
| Xiaozhong Liu | Addresses of individuals are not displayed. | 2,173,775 |
| Total number of shares in which substantial shareholder is interested under section 317 and 318: |
913,991,668 |
|
| |
| 24.
Date of filing this Form 3A: |
22/06/2017
(dd/mm/yyyy)
|
| 26.
Number of attachments: |
1 |
| |